Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022

SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to discuss these results and provide a corporate update. Details of the event are as follows:

Date: Tuesday, August 9, 2022

Time: 1:30 p.m. Pacific / 4:30 p.m. Eastern

Toll-free: (800) 715-9871

Conference ID: 4116795

Webcast URL: http://investor.neoleukin.com/events

The archived audio webcast will be available on the Investor Relations section of the Neoleukin website approximately two hours after the event and will be available for replay for at least 30 days after the event.

About Neoleukin Therapeutics, Inc.

Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin’s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website: www.neoleukin.com.

Contacts:

Media
Julie Rathbun
206-769-9219
jrathbun@neoleukin.com

Investors
Solebury Trout
Alexandra Roy
617-221-9197
aroy@soleburytrout.com

Staff

Recent Posts

LG EXPANDS MENTAL HEALTH SUPPORT FOR NCAA FINAL FOUR HOST SCHOOLS WITH NAMI PARTNERSHIP

LG continues its commitment to supporting mental health awareness, providing resources and support for students…

16 minutes ago

Scarless MTF Breast Augmentation Performed by Seattle Plastic Surgeon

Dr. Sajan Delivers Natural-Looking Transgender Breast Augmentation Without Chest ScarsSEATTLE, April 05, 2025 (GLOBE NEWSWIRE)…

3 hours ago

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified delayed-start analysis indicate…

3 hours ago

BREAKTHROUGH PRIZE ANNOUNCES 2025 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS

"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis…

12 hours ago

Breakthrough Prize Foundation Announces Student Winner of 10th Annual Breakthrough Junior Challenge Science Video Competition

Jasmine Eyal, Age 16, of Singapore, Receives Top Honors and $400,000 in Education Prizes for…

12 hours ago

Arialief Reviews (SHOCKING REPORT!) Is This Sciatic Nerve Relief Supplement Safe or Overhyped Hoax?

HONOLULU, Hawaii, April 05, 2025 (GLOBE NEWSWIRE) -- Arialief is nutritional support specifically designed to…

1 day ago